Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
XENE · against 289 other Healthcare companies of similar size
Ranked #222 of 290 · scores higher than 3% of peers
Bars: peers in each 10-point band of the valuation score69 peers with a valuation score of 0–9, including XENE · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | XENE | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 286 reported | -12.4% | 2.5% | 8% | 30% | |
| EBITDA yieldHigher is better · 285 reported | -15.8% | 4.7% | 4% | 50% | |
| Free cash flow yieldHigher is better · 150 reported | -9.1% | 0.8% | 11% | 20% | |
| Book yieldHigher is better · 284 reported | 33.6% | 28.6% | 56% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 1 | 40.2B MXN (≈$2.2B) | 99 | 71 | |
| 5 | 21.1B HKD (≈$2.7B) | 98 | 67 | |
| 222 | 2.2B USD | 8 | 35 | |
| 222 | 1.9B USD | 8 | 42 | |
| 222 | 2.8B USD | 8 | 51 | |
| 222 | 2.0B USD | 8 | 29 | |
| 222 | 3.7B USD | 8 | 28 | |
| 222 | 2.3B USD | 8 | 27 | |
| 222 | 2.5B USD | 8 | 31 | |
| 222 | 2.2B USD | 8 | 20 | |
| 283 | 18.5B CNY (≈$2.6B) | 7 | 37 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score